The study’s retrospective nature, the small number of patients, the single-center design, the variable number of postoperative adjuvant therapy between groups, and the lack of in vitro studies to demonstrate the mechanistic pathways of CXCL12 action in cancer cells (e.g., EMT) are limitations of the present study. The gene discussed is CXCL12; the disease is cancer.